Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingPhase 2interventionalRules rewrite

Phase 2: testing Semaglutide for Opioid Use Disorder

The is a pilot, 12-week, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, randomly assigned trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching dummy treatment (placebo) (n=23). The primary aim is to determine the effects of semaglutide on cue-reactivity among individuals with OUD.

Official registry: https://clinicaltrials.gov/study/NCT06639464 · Brigham and Women's Hospital · enrollment listed as 46

What this phase means

Phase 2: researchers already know a roughly safe dose (from phase 1). This stage asks whether the treatment actually helps the condition, and watches side effects more closely.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Semaglutide, or Placebo. The registry lists allocation as randomized. The is a pilot, 12-week, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment, randomly assigned trial of individuals with opioid use disorder (OUD) newly initiating buprenorphine to receive either weekly injections of semaglutide (n=23) or matching dummy treatment (placebo) (n=23).

They plan to enroll about 46 people at Boston. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Semaglutide for the Treatment of Opioid Use Disorder: A Pilot Randomized Controlled Trial

Interventions: Semaglutide, Placebo

Primary outcome (registry wording): Cue-induced Cravings for Opioids

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • English-speaking adults aged 18 or older
  • DSM-5 diagnosis of severe opioid use disorder (OUD)
  • Receiving buprenorphine ≥16 mg/day or methadone ≥70 mg/day for at least 30 days prior to enrollment
  • Planning to continue buprenorphine or methadone treatment throughout the study
  • Willing to bring buprenorphine prescriptions to visits for dose counts (if applicable)
  • Willing to authorize communication between the study team and their MOUD prescriber via a 42 CFR release

Public study contact (from the registry)

Joji Suzuki

617-732-5752

jsuzuki2@bwh.harvard.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseBethesda, Maryland
Study of Systemic Lupus Erythematosus

This protocol will evaluate patients with systemic lupus erythematosus (SLE) and their relatives to learn more about how the disease develops and changes over time. It will also study genetic factors that make a person susceptible to SLE.

NCT00001372 · Official ClinicalTrials.gov record · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

RecruitingNot a traditional drug phaseWashington D.C., District of Columbia
Familial Mediterranean Fever and Related Disorders: Genetics and Disease Characteristics

This study is designed to explore the genetics and pathophysiology of diseases presenting with intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this natural history study: 1) patients with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 7 years of age or older.

NCT00001373 · Official ClinicalTrials.gov record · National Human Genome Research Institute (NHGRI)

FAQ about this NCT record

Is NCT06639464 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT06639464?

Phase 2. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT06639464?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary